Real-time Estimate
Other stock markets
|
5-day change | 1st Jan Change | ||
86.12 USD | -2.01% | -2.10% | +12.96% |
23/05 | Some of the biggest splits in Corporate America | RE |
22/05 | Citigroup Upgrades Edwards Lifesciences to Buy From Neutral, Adjusts Price Target to $105 From $98 | MT |
Summary
- The company has strong fundamentals. More than 70% of companies have a lower mix of growth, profitability, debt and visibility.
- According to Refinitiv, the company's ESG score for its industry is good.
Strengths
- Before interest, taxes, depreciation and amortization, the company's margins are particularly high.
- Margins returned by the company are among the highest on the stock exchange list. Its core activity clears big profits.
- Thanks to a sound financial situation, the firm has significant leeway for investment.
- The average price target of analysts who are interested in the stock has been strongly revised upwards over the last four months.
- Considering the small differences between the analysts' various estimates, the group's business visibility is good.
- The group usually releases upbeat results with huge surprise rates.
Weaknesses
- The company's valuation in terms of earnings multiples is rather high. Indeed, the firm is getting paid 33.24 times its estimated earnings per share for the ongoing year.
- The company's "enterprise value to sales" ratio is among the highest in the world.
- In relation to the value of its tangible assets, the company's valuation appears relatively high.
- The valuation of the company is particularly high given the cash flows generated by its activity.
Ratings chart - Surperformance
Chart ESG Refinitiv
Sector: Advanced Medical Equipment & Technology
1st Jan change | Capi. | Investor Rating | ESG Refinitiv | |
---|---|---|---|---|
+12.96% | 52.96B | B+ | ||
+6.32% | 215B | B | ||
+9.83% | 187B | B- | ||
+18.06% | 143B | B- | ||
+29.49% | 110B | A- | ||
+1.48% | 64.68B | A- | ||
-0.16% | 49.84B | B+ | ||
-5.76% | 38.32B | A | ||
+0.54% | 35.86B | - | ||
+19.66% | 30.75B | B+ |
Financials
Valuation
Momentum
Consensus
Business Predictability
Environment
Governance
Controversy
Technical analysis
- Stock Market
- Equities
- EW Stock
- Ratings Edwards Lifesciences Corporation